echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Kangtai Bio's oral five-valent reassortant rotavirus live attenuated vaccine was approved for clinical use

    Kangtai Bio's oral five-valent reassortant rotavirus live attenuated vaccine was approved for clinical use

    • Last Update: 2021-12-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 17, Kangtai Biologics issued an announcement stating that the oral five-valent reassortant rotavirus live attenuated vaccine (Vero cells) developed by it and its wholly-owned subsidiary Minhai Biotechnology recently obtained the "Clinical Medicines" issued by the National Medical Products Administration.
    Test Approval Notice
    .


    The vaccine is used to prevent infantile diarrhea caused by rotavirus infection in infants and young children 6 weeks of age and older


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.